VivoSeq
Metabolic & Endocrine

Type 2 Diabetes Mellitus (T2DM)

2

Pipeline Programs↗

12

Active Trials↗

5

Companies Involved↗

Type 2 Diabetes Mellitus (T2DM) is an early-stage landscape with 2 programs across 5 companies. The most active players are Boehringer Ingelheim, Eli Lilly, Ann-Marie Rosland.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

43/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

PreclinicalA

Ann-Marie Rosland

0 programs

PreclinicalE

Endogenex, Inc.

0 programs

PreclinicalU

Universiti Teknologi Mara

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

SGLT2 Inhibitor

Eli Lilly

Phase 11

Empagliflozin

Boehringer Ingelheim

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

19

clinical trials

Completed7 · 37%
Recruiting6 · 32%
Not yet recruiting3 · 16%
Enrolling by invitation2 · 11%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

An Exploratory Clinical Study Assessing the Safety and Preliminary Efficacy of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Adult Type 2 Diabetes Mellitus
Recruiting·PPeking University First Hospital·Preclinical·NCT07693036·66 enrolled
ARISE: Achieving Routine Intervention and Screening for Emotional Health: Randomized Controlled Trial
Recruiting·UUniversity of Chicago·Preclinical·NCT06887049·1,250 enrolled
A Preliminary Clinical Study Protocol for Evaluating the Efficacy and Safety of Pulse Electric Field Ablation Systems in Treating Adult Type 2 Diabetes Mellitus With Suboptimal Drug Control
Recruiting·SShanghai East Hospital·N/A·NCT07678866·20 enrolled
Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy
Recruiting·UUniversity of Alabama at Birmingham·Preclinical·NCT06628453·564 enrolled
Effects of Continuous Glucose Monitoring on Patients With Type 2 Diabetes Treated With Insulin During Post-Discharge Transition: A Multicenter Randomized Controlled Trial
Recruiting·SShanghai 6th People's Hospital·Preclinical·NCT07414277·160 enrolled
Validation of NOURISH Project's Culturally Tailored Meals on Postprandial Glycemic Response Using Continuous Glucose Monitoring: A Quantitative and Qualitative Study
Recruiting·SStanford University·Preclinical·NCT06836479·30 enrolled
Integrative Genetic, Molecular and Behavioural Determinants of Cognitive Decline in Type 2 Diabetes: SGLT2 Inhibitors as a Model for Secondary and Tertiary Prevention (SaveMinD)
Active, not recruiting·UUniversity of Primorska·Preclinical·NCT07694596·200 enrolled
Clinical Validation of AI-assisted Antidiabetic Drug Consultation System-1
Not yet recruiting·NNational Taiwan University Hospital·Preclinical·NCT07684690·400 enrolled
Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology
Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07670871·440 enrolled
The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM): Rationale and Study Protocol for a Randomized Controlled Trial
Not yet recruiting·UUniversiti Teknologi Mara·Preclinical·NCT07664501·56 enrolled
Empowering Adults With Diabetes: Achieving Self-management Success Through Data-Driven Behavior Change, Pilot Randomized Control Trial
Enrolling by invitation·—·Preclinical·NCT06848361·80 enrolled
Endogenex PULSE Registry
Enrolling by invitation·EEndogenex, Inc.·N/A·NCT07197775·500 enrolled
Postprandial Glycemic and Physiological Responses to Walking With a Wearable Hip Exoskeleton in Patients With Type 2 Diabetes: A Randomized Crossover Proof-of-Concept Study
Completed·CCHA University·Preclinical·NCT07692802·14 enrolled
Effectiveness of and Implementation Strategies for 'Disfrutando': A Culturally Tailored, Bundled Intervention to Address Type 2 Diabetes Mellitus in High-burden Populations
Completed·UUniversity of Missouri-Columbia·Preclinical·NCT07023406·31 enrolled
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover Oral Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fasting Condition.
Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07694115·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)